Page 86 - Annual report 2021-22

Annual Report 2021-22 |

Neeru Saini’s group intend to investigate the molecular mechanisms underlying PARPi action and they
are in the process of generating drug resistant (olaparib & cisplatin) breast cancer cell lines. They have
started with MDA-MB 231 and cells are cultured in drug-containing media (5 uM, based on literature
as well as IC50) for three consecutive days and media was changed daily to remove dead cells. After
72 hours, the drugs were removed and cells are being maintained in drug free media. This process is
being repeated till resistant cell lines are obtained. Once established, they will check the resistance 69
using stemness markers and do profiling studies. To enable targeted therapies for Indian breast
cancers there is an unmet need to understand the characteristics of this disease within the Indian
population. The present study plans to do a whole genome, epigenome and transcriptome sequencing
of Indian breast cancer patients.

“It is my belief that the basic knowledge that we’re providing to the

world will have a profound impact on the human condition and the

treatments for disease and our view of our place on the biological
continuum.” — Craig Venter